Sanofi India Shareholders Back Opella Deals and Director Pay with Overwhelming Vote

Shareholders of Sanofi Consumer Healthcare India Ltd have overwhelmingly approved key transactions with Opella Healthcare entities and changes to director pay. The resolutions passed with over 99% of votes, signaling strong stakeholder confidence in these corporate actions.

Details of the Votes

Sanofi Consumer Healthcare India's shareholders gave their decisive approval for two crucial resolutions regarding transactions with Opella Healthcare India Private Limited and Opella Healthcare International SAS. The first resolution received 99.9487% support, followed by 99.9415% for the second. Shareholders also approved changes to the pay limits for Non-Executive Directors and Managing Director Mr. Himanshu Bakshi. These pay adjustments saw overwhelming backing, with Resolution 3 passing at 99.9927% and Resolution 4 at 99.9801%. The voting results were based on a scrutinizer's report dated April 23, 2026.

Significance of the Approvals

These approvals empower Sanofi Consumer Healthcare India to move forward with significant business dealings involving related Opella entities, which are important for the company's operations. The votes also formalize changes to the pay structure for key leaders like the Managing Director, aligning compensation with company performance and governance standards. The strong shareholder backing demonstrates confidence in the company's strategic path and its leadership compensation framework.

Company Background and Regulatory Context

Sanofi Consumer Healthcare India (SCHIL), established in May 2023, is a demerged entity focused on consumer health products. Its parent, Opella Healthcare Group, was Sanofi's former consumer health arm and now includes a partial stake held by CD&R, managing various over-the-counter medicines and supplements. Sanofi India operates under strict policies for transactions with related parties, requiring fair market value dealings and necessary approvals as mandated by Indian law and SEBI regulations. The company also noted general regulatory observations during the voting process: voting rights on shares transferred to the 'Investor Education and Protection Fund' remain frozen, and certain Foreign Portfolio Investors have restricted voting rights due to incomplete disclosures, as per SEBI circulars.

Competitive Landscape

Sanofi Consumer Healthcare India operates within a competitive Indian pharmaceutical market. Its key rivals, with substantial consumer healthcare portfolios, include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Ltd, and Lupin Ltd.